|Bid||0.00 x 3000|
|Ask||0.00 x 1100|
|Day's Range||3.00 - 3.04|
|52 Week Range||2.03 - 6.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.55|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 20) Avanos Medical Inc (NYSE: AVNS ) Becton Dickinson and Co (NYSE: ...
DOYLESTOWN, Pennsylvania, Aug. 20, 2018-- ProPhase Labs, Inc. today reported its financial results for the three and six months ended June 30, 2018. Net sales from continuing operations were $3.2 million ...
Based on its review, the OTC health care products company has determined that its income tax expense was understated and its net income was overstated.
DOYLESTOWN, PA, Aug. 14, 2018-- ProPhase Labs, Inc., a vertically integrated and diversified branding, marketing and technology company with deep experience in over-the-counter dietary supplements and ...
After looking at ProPhase Labs Inc’s (NASDAQ:PRPH) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / ProPhase Labs, Inc. (NASDAQ: PRPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 21, 2018 at 11:00 AM Eastern Time. ...
ProPhase Labs Inc. is buying back $4.5 million of its common stock, completing a tender offer announced earlier this month. The Doylestown, Pa., natural health products company said Thursday it has accepted for purchase about 1.95 million shares at $2.30 per share. ProPhase is the original developer of Cold-Eeze zinc lozenges for cold suffers.
ProPhase Labs Inc (NASDAQ:PRPH) delivered an ROE of 70.52% over the past 12 months, which is an impressive feat relative to its industry average of 16.15% during the same period.Read More...
Categories: Yahoo FinanceGet free summary analysis ProPhase Labs, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ProPhase Labs, Inc. – Mannatech, Incorporated, Reliv’ International, Inc., USANA Health Sciences, Inc., Nature’s Sunshine Products, Inc., Cyanotech Corporation, XOMA Corporation and True Drinks Holdings, Inc. (MTEX-US, RELV-US, ... Read more (Read more...)
ProPhase Labs Inc (NASDAQ:PRPH) is trading with a trailing P/E of 2.4x, which is lower than the industry average of 24.1x. While this makes PRPH appear like a great stockRead More...